Trans-10, cis-12 conjugated linoleic acid causes inflammation and delipidation of white adipose tissue in mice: a microarray and histological analysis by LaRosa, P. Christopher et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Faculty Publications, Department of Statistics Statistics, Department of
2006
Trans-10, cis-12 conjugated linoleic acid causes
inflammation and delipidation of white adipose
tissue in mice: a microarray and histological analysis
P. Christopher LaRosa
University of Nebraska - Lincoln, plarosa1@unl.edu
Jess L. Miner
University of Nebraska - Lincoln, jminer1@unl.edu
Yuannan Xia
University of Nebraska - Lincoln
You Zhou
University of Nebraska-Lincoln, yzhou2@unl.edu
Stephen D. Kachman
University of Nebraska-Lincoln, steve.kachman@unl.edu
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/statisticsfacpub
Part of the Other Statistics and Probability Commons
This Article is brought to you for free and open access by the Statistics, Department of at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Faculty Publications, Department of Statistics by an authorized administrator of DigitalCommons@University of
Nebraska - Lincoln.
LaRosa, P. Christopher; Miner, Jess L.; Xia, Yuannan; Zhou, You; Kachman, Stephen D.; and Fromm, Michael, "Trans-10, cis-12
conjugated linoleic acid causes inflammation and delipidation of white adipose tissue in mice: a microarray and histological analysis"
(2006). Faculty Publications, Department of Statistics. 48.
http://digitalcommons.unl.edu/statisticsfacpub/48
Authors
P. Christopher LaRosa, Jess L. Miner, Yuannan Xia, You Zhou, Stephen D. Kachman, and Michael Fromm
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/statisticsfacpub/48
Trans-10, cis-12 conjugated linoleic acid causes inflammation and delipidation
of white adipose tissue in mice: a microarray and histological analysis
P. Christopher LaRosa,1 Jess Miner,2 Yuannan Xia,1
You Zhou,1 Steve Kachman,3 and Michael E. Fromm1
1Center for Biotechnology, 2Department of Animal Science, and
3Department of Statistics, University of Nebraska, Lincoln, Nebraska
Submitted 1 May 2006; accepted in final form 21 July 2006
LaRosa, P. Christopher, Jess Miner, Yuannan Xia, You Zhou,
Steve Kachman, and Michael E. Fromm. Trans-10, cis-12 conju-
gated linoleic acid causes inflammation and delipidation of white
adipose tissue in mice: a microarray and histological analysis. Physiol
Genomics 27: 282–294, 2006. First published July 25, 2006;
doi:10.1152/physiolgenomics.00076.2006.—A combined histological
and microarray analysis of the white adipose tissue (WAT) of mice
fed trans-10, cis-12 conjugated linoleic acid (t10c12 CLA) was
performed to better define functional responses. Mice fed t10c12 CLA
for 14 days lost 85% of WAT mass, 95% of adipocyte lipid droplet
volume, and 15 or 47% of the number of adipocytes and total cells,
respectively. Microarray profiling of replicated pools (n  2 per
day diet) of control and treated mice (n 140) at seven time points
after 1–17 days of t10c12 CLA feeding found between 2,682 and
4,216 transcript levels changed by twofold or more. Transcript levels
for genes involved in glucose and fatty acid import or biosynthesis
were significantly reduced. Highly expressed transcripts for lipases
were significantly reduced but still abundant. Increased levels of
mRNAs for two key thermogenesis proteins, uncoupling protein 1 and
carnitine palmitoyltransferase 1, may have increased energy expendi-
tures. Significant reductions of mRNAs for major adipocyte regula-
tory factors, including peroxisome proliferator activated receptor-,
sterol regulatory binding protein 1, CAAT/enhancer binding pro-
tein-, and lipin 1 were correlated with the reduced transcript levels
for key metabolic pathways in the WAT. A prolific inflammation
response was indicated by the 2- to 100-fold induction of many
cytokine transcripts, including those for IL-6, IL-1, TNF ligands,
and CXC family members, and an increased density of macrophages.
The mRNA changes suggest that a combination of cell loss, increased
energy expenditure, and residual transport of lipids out of the adipo-
cytes may account for the cumulative mass loss observed.
lipid metabolism; gene expression; cell biology
DIETARY CONJUGATED LINOLEIC ACID (CLA), either as mixed
isomers or the specific trans-10, cis-12 isomer (t10c12 CLA),
dramatically reduces fat content in white adipose tissues
(WAT) in mice (10, 36) although results in humans have been
inconsistent (51, 52). Weight losses in WAT of up to 70% have
been reported in mice on diets containing 0.5–1% CLA (10,
50). In mice this reduction is due to altered energy metabolism
or transport and is not generally due to reduced feed intake (10,
17, 49, 51, 53, 54). CLA increases energy expenditure in whole
mice and is correlated with increases in the mRNAs for
mitochondrial uncoupling protein 1 and 2 (UCP1, UCP2) in
some studies (21, 47, 50) but not others (53). Proinflammatory
cytokines levels, including those of tumor necrosis factor
(TNF-) and interleukins 6 and 8 (IL-6 and IL-8) are increased
in response to CLA (4, 50).
At the cellular level, evidence supports either apoptotic loss
of cells (11, 18, 34, 50) or reduced triglyceride (TG) content in
surviving adipocytes (11, 50). Cumulative cellular TG levels
respond to changes in the balance of the cellular energy import,
export, or expenditure. Transcripts of genes involved in glu-
cose import and fatty acid biosynthesis are reduced in CLA-
treated cells (47, 50). Key metabolic genes that are downregu-
lated by CLA include glucose transporter 4 (Glut4), acetyl-
CoA carboxylase, and fatty acid synthase, whereas key
regulatory genes that are downregulated include sterol regula-
tory binding protein 1 (SREBP1), peroxisome proliferator
activated receptor (PPAR)-, and CCAAT/enhancer binding
protein (C/EBP)- (see Ref. 22 for a recent review). Microar-
ray analyses of the genomic response of polygenic obese and
control mice generally confirmed the above observations at the
level of gene expression 5 and 14 days after CLA treatment in
adipose tissues (21). Despite the considerable progress at
describing the molecular responses to CLA its primary site of
action is still unknown.
In the present studies, we analyzed the retroperitoneal (RP)
WAT of C57BL/6J mice fed t10c12 CLA for times ranging
from 1 to 17 days. Cellular and gene expression changes were
determined using histological examination and microarrays
capable of detecting 34,000 transcripts. Delipidation and cell
loss both occurred, and up to 4,216 transcript levels changed by
twofold or more (P  0.01). These genes were grouped into
biochemical and signaling pathways to explain the cellular
changes observed in the WAT.
MATERIALS AND METHODS
Animals
All animal experiment protocols (#03-06-021) were reviewed and
approved by the Institutional Animal Care and Use Committee of
University of Nebraska-Lincoln and followed National Institutes of
Health guidelines for the Care and Use of Laboratory Animals
(Publications No. 80-23; revised in 1996). We housed 152 9-wk-old
male C57BL/6J mice (Charles River Laboratories) individually and
fed them pellets of modified AIN-93G (soy protein replaces casein,
Dyets) diet for 11 days before treatment initiation. Treatments were
either control diet AIN-93G or t10c12 CLA diet consisting of control
diet with 0.5% of the soy oil substituted with 0.5% t10c12 CLA
(Nu-Chek Prep, Elysian, MN). Mice were allowed to feed ad libitum
until death by CO2 asphyxiation. We killed 20 mice on each of days
1, 2, 3, 4, 7, 10, and 17. Both epididymal (EP) and RP fat pads were
excised, weighed, and then frozen in liquid nitrogen for subsequent
mRNA analyses. Twelve mice were killed on day 14 to obtain tissue
for histological analyses as described later. The weight and feed data
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were analyzed with the PROC MIXED procedure of SAS (SAS Inst.,
2003) as a 7  2 factorial with heterogeneous variances across days.
The model included main effects for days and treatment along with
the day by treatment interaction. Contrasts were used to compare
control and t10c12 CLA-fed mice within day.
Histological and Immunofluorescence Microscopy and Quantitative
Image Analysis
Each pair of the RP tissues from mice fed either control or t10c12
CLA diets for 14 days (six mice for each control and treatment group)
was isolated, weighed, and immediately fixed for quantitative image
and immunochemical analyses. One of the two RP tissues from each
of the mice was fixed in 3.7% formaldehyde in PBS and processed for
paraffin embedding, sectioning, and standard hematoxylin and eosin
(H&E) staining. These H&E-stained sections were used for quantita-
tive measurement of the mean diameters of adipocytes. The number of
adipocytes, defined as the cells containing empty areas from which the
fat contents were removed during the dehydration process, in a fixed
area was counted, and the cell diameter was determined from sections
of each individual RP section for a total of 63 images each for control
and treated samples, using a SoftImaging image analysis program
(Olympus).
The other RP fat pad from each mouse was fixed in 2.5% glutar-
aldehyde in PBS, washed, and stained with 1% Sudan black dye (for
visualizing the fat content) in PBS containing 0.5% Triton X-100 at
room temperature for 3 h. This set of RP tissues was washed in PBS
and stained with 2 M Sytox green (for visualizing the DNA in the
nucleus) in PBS containing 0.5% Triton X-100 overnight at 4°C. The
stained sections were then used for quantitative comparison of num-
bers of cells, as determined by the density of the stained nuclei in a
given volume, in each of the RP tissues.
To determine the cell density of the RP tissues a series of 512 
512 frames from confocal optical images was collected with a 10
lens using a Z-step of 5 m for 40–50 m in depth using an
Olympus FV confocal laser scanning system on an IX80 inverted
microscope. Dual laser lines were used to collect two color images
simultaneously: a 405-nm line was used for fluorescence of fat content
stained with Sudan black dye and a 488-nm line for Sytox green-
stained nuclei. Final extended focusing images (four from the larger
control tissues and three from the smaller treatment tissues for each
mouse RP tissue) covering 1,200 m  400 m  40 m regions of
the RP tissues were used for quantitative image analysis with a
SoftImaging image analysis program (Olympus). The numbers of
nuclei within the areas of fluorescence were determined from each
image, and an average cell density was obtained from 24 control
images and 18 treated images.
For immunofluorescence labeling of macrophages, paraffin sec-
tions from the same adipose tissues used for morphological analysis
were processed for conventional immunofluorescence labeling using
rat antibodies to mouse CD68 (1:50 dilution; Serotec, Raleigh, NC),
a known marker for monocytes and macrophages. Cy5-conjugated
goat anti-mouse IgG secondary antibodies (Jackson ImmunoResearch,
West Grove, PA) were used for fluorescence detection of the CD68,
and a DNA-staining fluorescent dye Sytox green (Molecular Probes)
was used for nuclear counterstain. We collected 50 images from each
group (control and t10c12 CLA-treated), and CD68-labeled cells were
counted and averaged.
RNA Isolation and Labeling
RNA for each time point was isolated from two control and two
treatment samples for analysis on four microarrays. The two control
and two treatment samples consisted of RP tissues from five pooled
mice for each sample, requiring a total of 20 mice for the four samples
taken at each time point. Total RNA was extracted from the frozen RP
tissues of each sample using TRIzol (Invitrogen) reagent. We used 15
g of total RNA to produce labeled cRNA for hybridization to
Affymetrix GeneChip Mouse Genome 420 2.0 arrays with the man-
ufacturer’s protocols (Affymetrix).
Microarray Data Analysis
Affymetrix GeneChip Operating Software generated the image and
probe set signal values as cel files, and the cel files were processed
with the affy package (13) using the robust multiarray analysis (RMA,
Ref. 24) to generate normalized signal values. The RMA signal values
were log2 transformed. The arrays were screened for outlying arrays
by plotting the M  (X 	 Y) and A  (X 
 Y)/2 values for pairs of
arrays where X and Y are the transformed RMA expression values.
One of the day 2 control arrays was inconsistent with the other arrays
on day 2 and that array was removed from further analysis. To detect
differentially expressed genes the transformed RMA expression val-
ues were analyzed with an empirical Bayes linear model (45, 46). The
linear model included fixed effects for days and treatment nested
within days. A gene was viewed as differentially expressed on a given
day either if it had a large effect on that day or if it had a consistent
effect with an adjacent day. A single day effect was quantified by the
moderated t-statistic for the treatment effect on that day. A consistent
effect with 2 days was quantified as the minimum moderated t-statistic
for the 2 days. A consistent effect between adjacent days was then
defined to be the maximum of the effects for a day before and the day
after. A P value for a gene being differentially expressed on a day was
then calculated as the probability of obtaining a value smaller than the
observed minimum of the single day P value and the consistent effect
P value if the gene was not differentially expressed. A gene was
considered differentially expressed if the false discovery rate-adjusted
P value was 5%. The series record of the data submitted to the
National Center for Biotechnology Information Gene Expression
Omnibus is GSE4671.
Pathway analysis. The sorted lists of up- and downmodulated
genes containing the Affymetrix probe set identifiers and their aver-
aged signal log ratios (log2) were entered into the Ingenuity Pathway
Analysis software (Ingenuity Systems, www.ingenuity.com) to help
organize them into known biological pathways. When probe sets
redundantly represented a single gene, the probe set with the maxi-
mum signal log ratio was used in the analysis. Probability scores for
each network or functional grouping are calculated as to the chances
of the mRNA abundance changes predicting these interactions and
networks. A full discussion of the statistical methodologies employed
can be found in the supplemental files of Calvano et al. (6).
Quantitative RT-PCR. First-strand cDNA synthesis used Moloney
murine leukemia virus reverse transcriptase and 0.5 g of total RNA
primed with oligo (dT)17 (Invitrogen). The single-strand cDNA pool
was diluted 10- to 100-fold and used as template for quantitative
real-time PCR. Relative levels of the target mRNAs were determined
using a Bio-Rad iCycler iQ and the iQ SYBR Green Supermix
reagent. The target mRNA was normalized relative to the levels of the
housekeeping gene 2-microglobulin.
RESULTS
T10c12 CLA Causes Significant Loss of Adipose Tissue
Without Body Weight Loss or Reduced Feed Intake
Neither body weight nor feed intake was influenced by
t10c12 CLA (Fig. 1A and Supplemental Fig. 1; the online
version of this paper contains supplemental data). Conversely,
weights of the RP and EP fat pads from t10c12 CLA-fed mice
were 25% of the control (Fig. 1B).
T10c12 CLA Treatment Causes Lipid Depletion and Cell
Loss in RP Tissues
Fixed RP tissue sections were stained with Sytox green to
visualize the nuclei (Fig. 2, A and B) and Sudan black to
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visualize the adipocytes (data not shown). We found nuclear
densities of 1.5 and 5.7 nuclei per 353 m3 for the control (n
6 mice, 24 images) and t10c12 CLA-treated tissues (n  6
mice, 18 images), respectively. The average weights of the
control (n  6) and t10c12 CLA-treated RP tissues (n  6)
were 157 and 23 mg, respectively. The almost fourfold in-
crease in cell density is offset by the 6.8-fold reduction in
tissue weight such that the t10c12 CLA-treated RP tissues
contained only 53% of the number of total cells in the control
tissue due to the much smaller mass of the t10c12 CLA-treated
tissue.
H&E-stained sections were used for quantitative measure-
ment of the cell diameters of the adipocytes. The average
diameter of the adipocytes (measured from 63 frames of
images from 6 mice from each group) was reduced from 46 m
for the control to 17 m for the t10c12 CLA-treated cells. This
corresponds to a 95% reduction in cell volume. The reduced
adipocyte cell sizes caused the t10c12 CLA-treated WAT to
have a higher density of nonadipocyte cell types (Fig. 2, C and
D). The majority of the adipocytes were retained in the WAT
as the ratio of the number of adipocytes in the t10c12 CLA-
treated to control tissues was determined to be 0.85. The
apparent 15% reduction in the number of adipocytes could be
due to either cell death or a change in the adipocytes’ appear-
ance due to loss of the distinguishing lipid droplet.
T10c12 CLA Treatment Increases the Density of
Macrophages in RP Tissues
T10c12 CLA treatment induces a strong inflammatory re-
sponse as described below in the microarray results. The
involvement of macrophages in this process was examined by
confocal immunofluorescence microscopy. We counted the
monocytes/macrophages containing CD68 antigen in 50 im-
ages each for the control and t10c12 CLA-treated adipose
tissues. Most control tissue sections lacked macrophages al-
though some images contained one or two macrophages (Fig.
2E). Macrophages were more abundant in t10c12 CLA-treated
tissues, and in some cases six or seven macrophages were
found in the same image (Fig. 2F). Additionally the t10c12
CLA-treated samples contained more monocytes in blood
vessels (Fig. 2G) than in control sections (data not shown). We
counted 6.5 times more CD68-labeled cells in the t10c12
CLA-treated samples compared with the controls. The t10c12
CLA-treated RP tissue weighed 6.8 times less than control
tissue, indicating both tissues contained similar numbers of
macrophages despite their much higher density in the t10c12
CLA-treated WAT. The number of macrophages was calcu-
lated from the tissue images to be 4% of the cells in control
tissues and 8% of the cells in t10c12 CLA-treated tissues,
which had lost 47% of their total cells as described above.
The above histological interpretation is supported by an
increase in the expression of genes specific for macrophages
(Supplemental Table 7). The microarray data show six- and
threefold increases in CD68 (20) and F4/80 (28), respectively,
as early as 2 days after t10c12 CLA feeding and persisting at
10-fold for the duration of the experiment. Similar increases
are seen for macrophage scavenger receptor 1 (14) and CCL2
[monocyte chemoattractant protein (MCP)-2, see Ref. 26], and
these increase by 1 day after initiating t10c12 CLA feeding
(Supplemental Table 7). The increases in the mRNA levels of
these genes is larger than the estimated twofold increase in the
percentage of macrophage cells, presumably due to increased
expression levels of these mRNAs in activated macrophages.
Microarray Analysis of t10c12 CLA-Induced RP
Transcriptome Changes
The analysis of the GeneChip Mouse Genome 420 2.0
microarrays showed thousands of transcripts are differentially
expressed as early as the first time point at 24 h after feeding
mice t10c12 CLA, and most of these transcripts maintained
these changes for the duration of the 17-day experiment (Table
1). These large-scale changes in gene expression are consistent
with the large-scale remodeling of the RP tissue that occurs
over the treatment period. The significant changes observed for
mRNAs from genes in known signaling pathways and the
putative role of these pathways are shown (Table 2). Similarly,
the significant changes in Kyoto Encyclopedia of Genes and
Genomes-annotated metabolic pathways are shown (Table 3).
Transcript levels from genes in individual metabolic pathways
tended to increase or decrease as a group, and the majority of
Fig. 1. Body weight changes in control (}) and trans-10, cis-12 conjugated
linoleic acid (CLA)-fed mice (■) (A) and weight changes of retroperitoneal
(RP) adipose tissue of control (}) and CLA-fed mice (■) and in epididymal
(EP) control (Œ) and CLA-fed mice({) (B). The error bars delineate SE.
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the pathways showed decreases in the transcript levels (Tables
2 and 3). As will be presented below, the directional changes
in gene expression are generally conserved across multiple
time points, indicating the induction or repression of individual
genes are consistent over these time periods.
Lipid biosynthetic pathways. The majority of the genes in
lipid biosynthetic pathways show decreased mRNA levels.
These include the fatty acid biosynthesis pathways, pentose
phosphate pathway, citrate cycle, oxidative phosphorylation,
propanoate, butanoate, and other pathways feeding acetyl-CoA
or other components necessary for fatty acid and triglyceride
biosynthesis (Table 3). Rate-limiting enzymes showing
strongly reduced mRNA levels include those for ATP citrate
lyase and acetyl Co-A carboxylase- and - (Table 4). Other
pathways associated with sterol biosynthesis and mitochondrial
function were predominantly downregulated, including path-
ways associated with leucine, valine, and isoleucine degrada-
tion, ubiquinone biosynthesis, and several pathways involves
with amino acid metabolism (Table 3).
Lipolysis. Downregulation of transcripts for the key lipolytic
enzymes involved in transport of fatty acids out of the adipo-
cytes included those for hormone sensitive lipase, adiponutrin,
desnutrin, and monoglyceride lipase (Table 4). Monoglyceride
lipase is normally highly expressed as its transcript levels are
more abundant than 99% of the mRNA signals. Hormone-
sensitive lipase is also highly expressed as it is in the top 95th
percentile. Even after two- to sevenfold declines, their mRNA
levels are still in the 90th percentile of the most abundant
mRNA signals suggesting that some residual lipase activity
may still be present in this pathway. The 25–40% downregu-
lation of lipoprotein lipase would be consistent with a decline
in lipid filling capacity. In contrast there is a significant
upregulation of lipase A, the lysosomal acid lipase (also known
as cholesterol ester hydrolase). This transcript is among the top
10% of the most abundant transcripts in the controls and rises
Fig. 2. Representative images showing differences in nuclear density (A and B), a comparison of adipose tissue histology (C and D), and the distribution of
monocytes/macrophage as detected with antibody to CD68 (E1, F1, and G1; as indicated by arrows) and when overlaid with a nuclear stain (E2, F2, and G2)
between the control and CLA-treated RP tissues. The significant increase in cell density in response to CLA, as indicated by green fluorescence-labeled nuclei
(A and B), is due to both reduction of fat content and increase in number of nonadipocytes as shown in D. Among the nonadipocyte cells, the density of
macrophages was significantly higher in the CLA-treated RP tissues (F) compared with that in control RP tissue sections (E). In addition, increased numbers
of monocytes were also found in blood vessels in the CLA-treated RP tissues (G). Scale bars  30 m (A and B have the same magnification, as do C and D).
Table 1. Change in mRNA levels in RP tissues
of CLA-fed mice
Days of
Feeding
Number of mRNAs That Change
Total Increased
or Decreased Increased Decreased
1 5407 (2682) 2530 (1212) 2877 (1470)
2 6755 (3108) 3633 (1792) 3122 (1316)
3 8750 (3955) 4330 (2068) 4420 (1887)
4 9097 (4216) 4773 (2385) 4324 (1831)
7 7766 (3290) 3969 (1905) 3797 (1385)
10 8107 (3388) 4130 (1915) 3977 (1473)
17 7270 (3495) 3902 (2111) 3368 (1384)
An mRNA level was considered differentially increased or decreased if the
false discovery rate-adjusted P value was 0.05. Numbers in parentheses
represent values with at least a 2-fold signal change (P  0.01). RP, retroper-
itoneal; CLA, conjugated linoleic acid.
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to an even higher level in t10c12 CLA-fed mice. The increased
transcript abundance of this gene may be associated with
phagocytotic immune cells and vascular cells rather than
adipocytes.
Apoptosis. Pathway analysis indicated that a number of
genes involved in apoptotic signaling were differentially ex-
pressed (Table 2 and Supplemental Table 5). There is an
induction of a number of death receptors and their ligands
Table 2. mRNA changes in canonical signaling pathways in RP tissues of CLA-fed mice
Canonical Signaling Pathways Interpretive Biological Role
Days after CLA Feeding
mRNA
Change
Summary
1 2 3 4 7 10 17
Number of mRNAs Changed
PPAR signaling (65) adipocyte dedifferentiation possibly due to inflammation
factors and NF-B signaling
27* 17 22 25 18 22 20 mixed
Chemokine signaling (56) inflammation responses of adipocytes, macrophages and other
cells
26* 23 31* 34* 28* 28* 26* mostly up
PI3K/AKT signaling (88) activation of IL-6, insulin-receptor signaling 35* 34* 44* 43* 38 37 35 mixed
ERK/MAPK (121) activation of IL-6, insulin-receptor signaling, IL-4, IL-2
signaling
45* 56* 65* 55* 55* 55* 52* mixed
B-cell receptor signaling (114) immune cell activation and infiltration 41* 47* 57* 59* 50* 51* 49* mostly up
IL-6 signaling (68) inflammatory responses 26* 21 28 27 27 22 21 mostly up
IL-2 signaling (40) inflammatory responses 15 14 19 21 21* 21* 19* mixed
IL-4 signaling (36) inflammatory responses 14 12 19 21* 23* 22* 21* mostly up
JAK/Stat signaling (47) inflammatory responses 19* 16 27* 27* 26* 27* 25* mixed
Insulin receptor signaling (102) insulin resistance 36* 36 49* 46 45 43* 43* mixed
IGF-1 signaling antiproliferation 24 26 33* 35* 33* 32* 29* mixed
VEGF signaling (66) antiproliferation of vasculature 25 27 34* 36* 35 39* 29 mixed
Cell cycle: G2/M DNA damage
checkpoint signaling (34)
antiproliferation, potentiates apoptosis or DNA repair 7 16 18 21* 17* 18* 17* mostly up
Apoptosis signaling (68) potentiates associated with deproliferation 31* 27 34* 35* 28 26 25 mixed
Integrin signaling (164) antimitotic/proliferation, cell cycle regulation 39 51 68 72 69* 68 61 mixed
Sonic hedgehog signaling (22) antiproliferation of vasculature 8 8 13* 13* 11 10 10 mixed
Nitric oxide signaling in the
cardiovascular system (41)
insulin resistance, anti-proliferation of vasculature 17* 17 26* 26* 21 16 16 mixed
Listed under Canonical Signaling Pathways are the conceptual signaling pathways with the total number of genes in the Kyoto Encyclopedia of Genes and
Genomes (KEGG)-derived pathways listed in parenthesis. *Gene groups where P value is 0.05.
Table 3. mRNA changes in metabolic signaling pathways in RP tissues of CLA-fed mice
Metabolic Pathway (number of genes in pathway)
Days after CLA Feeding
1 2 3 4 7 10 17
Number of mRNAs Changed
mRNA Change
Summary
Leucine, valine and isoleucine degradation (58) 42* 45* 48* 45* 37* 40* 39* all decreased
Propanoate metabolism (57) 36* 39* 44* 42* 36* 35* 35* all decreased
Citrate cycle (27) 21* 23* 21* 20* 14* 14* 14* all decreased
Oxidative phosphorylation (139) 67* 76* 81* 64 41 39 35 most decreased
Ubiquinone biosynthesis (47) 28 30* 33 23 13 12 9 all decreased
Fatty acid biosynthesis (path 1, 18) 14* 14* 14* 13* 9 13* 13* all decreased
B-alanine biosynthesis (49) 24* 29* 31* 30* 25* 26* 24* most decreased
Butanoate metabolism (44) 23* 25* 26* 25* 24* 25* 21* all decreased
Fatty acid biosynthesis (path 2, 8) 7* 6* 6* 7* 7* 6* 6* all decreased
Alanine and aspartate metabolism (28) 15* 13 15 17* 16* 15* 13 most decreased
Pyruvate metabolism (69) 30* 35* 44* 41* 38* 34* 34* all decreased
Cysteine metabolism (12) 8* 8* 8* 7 6 6 6 mixed
Glutathione metabolism (61) 26* 31* 31* 28 24 27 25 most decreased
Glutamate metabolism (34) 16* 17* 17 19* 18* 15 13 mixed
Lysine metabolism (46) 20* 25* 29* 29* 24* 23* 22* most decreased
Histidine metabolism (32) 15* 18* 18* 19* 17* 16* 15* most decreased
Pantheonate metabolism (19) 10* 9 11 12* 9 10 9 mixed
One carbon by folate metabolism (19) 10* 9 12* 13* 13* 13* 12* mixed
Fatty acid metabolism (111) 41* 44* 50* 49* 43* 46* 49* most decreased
Riboflavin metabolism (17) 9* 9 11* 9 9 9 9 most decreased
Synthesis and degradation of ketone bodies (10) 6* 4 4 3 4 4 3 all decreased
Glycerolipid metabolism (79) 27 30 37* 39* 36* 33 33 mixed
Tyrosine metabolism (45) 16 18 22 23 20 22* 22* mixed
Aminosugar metabolism (25) 9 15* 17* 17* 15* 14* 14* most increased
Listed are the conceptual signaling pathways with the total number of genes in the KEGG-derived pathways listed in parenthesis. *Gene groups where P value
is 0.05.
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Table 4. mRNA changes in key genes in fatty acid and lipid biosynthesis in RP tissues of CLA-fed mice
Gene
Symbol Description Days of trans-10 cis-12 CLA Feeding
1 2 3 4 7 10 17
Fatty Acid, Glucose, or Lipid Transport mRNA Changes (fold-change; control  1.0)
ABCD2 ATP-binding cassette, sub-family D (ALD), member 2 0.2 0.4 0.2 0.2 0.3 0.2 0.2
SLC2A4 facilitated glucose transporter member 4, Glut 4 0.2 0.1 0.1 0.1 0.3 0.2 0.2
SLC2A5 facilitated glucose/fructose transporter member 5 0.3 0.2 0.1 0.2 0.2 0.3 0.2
FABP4 fatty acid binding protein 4, adipocyte, aP2 0.4 0.4 0.2 0.4 0.3 0.3 0.2
LRP8 low density lipoprotein receptor-related protein 8 9.2 3.2 3.2 2.8 n.c. n.c. n.c.
CAV1 caveolin 1 0.6 n.c. 0.8 0.7 0.6 0.6 0.6
CAV2 caveolin 2 0.6 0.7 0.6 0.6 0.5 0.5 0.5
MSR1 macrophage scavenger receptor 1 8.0 21.1 12.1 10.6 7.5 6.5 11.3
Lipolysis
ADPN adiponutrin 0.2 0.3 0.2 0.1 0.1 0.1 0.1
LIPE lipase, hormone-sensitive 0.2 0.3 0.2 0.3 0.3 0.2 0.1
LIPA lipase A, lysosomal acid, cholesterol esterase 2.0 9.2 17.1 11.3 9.8 9.8 8.6
MGLL monoglyceride lipase 0.2 0.4 0.3 0.3 0.3 0.3 0.3
LPL lipoprotein lipase 0.6 0.7 n.c. n.c. 0.7 0.8 0.8
PNPLA2 datatin-like phospholipase domain containing 2, 0.6 0.3 0.3 0.3 0.4 0.3 0.3
Lipogenesis, fatty acid biosynthesis and metabolism
ACACA acetyl-coenzyme A carboxylase alpha 0.3 0.2 0.1 0.2 0.2 0.2 0.2
ACACB acetyl-coenzyme A carboxylase beta 0.4 0.2 0.2 0.3 0.2 0.2 0.1
ACAD8 acyl-coenzyme A dehydrogenase family, member 8 0.5 0.4 0.5 0.4 0.5 0.4 0.6
ACSL1 acyl-coA synthetase long-chain family member 1 0.3 n.c. 0.5 0.6 0.7 0.6 0.7
ACAS2 acetyl-coenzyme A synthetase 2 0.4 0.2 0.3 0.3 0.2 0.1 0.1
ACAT1 acetyl-coenzyme A acetyltransferase 1 0.4 0.4 0.4 0.3 0.5 0.4 0.5
ACAT2 acetyl-coenzyme A acetyltransferase 2 0.3 0.3 0.2 0.4 0.3 0.2 0.2
ACLY ATP citrate lyase 0.2 0.2 0.1 0.2 0.2 0.2 0.1
ACO1 aconitase 1, soluble 0.4 0.5 0.5 0.4 0.4 0.4 0.5
ACSL1 acyl-CoA synthetase long-chain family member 1 0.3 n.c. 0.5 0.6 0.7 0.6 0.7
AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 0.2 0.5 0.4 0.5 0.5 0.4 0.4
CS citrate synthase 0.6 0.4 0.5 0.6 0.7 0.8 0.7
DF D component of complement (adipsin) 0.6 0.4 0.4 0.4 0.2 0.2 0.1
EHHADH enoyl-Co A, hydratase/3-hydroxyacyl coenzyme A 0.3 0.3 0.2 0.3 0.4 0.4 0.3
ELOVL6 ELOVL family member 6, elongation of long chain fatty 0.2 0.1 0.1 0.1 0.1 0.1 0.1
FABP4 fatty acid binding protein 4, adipocyte 0.4 0.4 0.2 0.4 0.3 0.3 0.2
FASN fatty acid synthase 0.5 0.3 0.3 0.3 0.3 0.3 0.3
GPD2 glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 0.2 0.1 0.1 0.1 0.3 0.3 0.2
HADH2 hydroxyacyl-coenzyme A dehydrogenase, type II 0.4 0.4 0.4 0.4 0.5 0.4 0.6
IDH3A isocitrate dehydrogenase 3 (NAD
) alpha 0.4 0.4 0.5 0.4 n.c. n.c. n.c.
LSS lanosterol synthase 0.3 0.5 0.4 0.5 0.8 0.6 0.6
MCCC2 methylcrotonoyl-coenzyme A carboxylase 2 (beta) 0.2 0.2 0.1 0.2 0.7 0.6 0.7
ME1 malic enzyme 1, NADP(
)-dependent, cytosolic 0.6 0.3 0.4 0.5 0.2 0.2 0.3
MGLL monoglyceride lipase 0.2 0.4 0.3 0.3 0.3 0.2 0.3
PC pyruvate carboxylase 0.4 0.1 0.2 0.2 0.3 0.3 0.3
PCK1 phosphoenolpyruvate carboxykinase 1 (soluble) 0.1 0.1 0.0 0.1 0.6 0.4 0.5
PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 0.5 0.3 0.3 0.4 0.4 0.4 0.3
PDK1 pyruvate dehydrogenase kinase, isoenzyme 1 0.2 0.2 0.2 0.3 0.5 0.4 0.4
SC5DL sterol-C5-desaturase 0.3 0.4 0.3 0.3 0.4 0.4 0.4
SCD stearoyl-CoA desaturase (delta-9-desaturase) 0.4 0.2 0.3 0.4 0.5 0.5 0.5
SCD2 stearoyl-coenzyme A desaturase 2 0.1 0.3 0.1 0.6 0.3 0.3 0.2
Beta Oxidation Genes
CPT1A carnitine palmitoyltransferase 1A (liver) n.c. 2.6 2.1 3.0 2.3 2.3 2.1
CPT1B carnitine palmitoyltransferase 1B (muscle) n.c. n.c. n.c. n.c. 3.0 3.2 1.6
CROT carnitine O-octanoyltransferase 0.5 0.7 0.7 0.7 n.c. n.c. n.c.
CPT2 carnitine palmitoyltransferase II 0.5 0.4 0.6 0.5 0.7 0.6 0.6
ECHS1 enoyl coenzyme A hydratase, short chain, 1, 0.4 0.2 0.3 0.4 0.6 0.5 0.4
CRAT carnitine acetyltransferase 0.3 0.3 0.3 0.4 n.c. 0.4 0.5
NDUFC2 NADH dehydrogenase (ubiquinone) 1, subcomplex 0.5 0.7 0.7 n.c. n.c. n.c. n.c.
NDUFV2 NADH dehydrogenase (ubiquinone) flavoprotein 2Da 0.7 0.7 0.7 n.c. n.c. n.c. n.c.
ACADM acyl-coenzyme A dehydrogenase, C-4 to C-12 straight 0.4 0.5 0.7 0.7 n.c. n.c. n.c.
HADHSC L-3-hydroxyacyl-coenzyme A dehydrogenase, short 0.6 0.5 0.5 0.5 0.8 0.6 0.6
AUH AU RNA binding protein/enoyl-coenzyme A hydratase 0.5 0.4 0.4 0.4 0.4 0.4 0.4
HADHB hydroxyacyl-coenzyme A dehydrogenase/3-ketoacyl- 0.5 0.5 0.6 n.c. n.c. n.c. n.c.
ACADVL acyl-coenzyme A dehydrogenase, very long chain 0.8 0.5 0.5 0.7 n.c. n.c. n.c.
ACADSB acyl-coenzyme A dehydrogenase, short/branched chain 0.7 0.3 0.4 0.3 0.4 0.4 0.4
ACADL acyl-coenzyme A dehydrogenase, long chain 0.6 0.5 0.7 0.8 n.c. n.c. n.c.
ACAD9 acyl-coenzyme A dehydrogenase family, member 9 0.5 n.c. 0.7 0.7 0.8 0.7 0.8
ACADL acyl-coenzyme A dehydrogenase, long chain 0.6 0.5 0.7 0.8 n.c. n.c. 0.4
n.c., no change.
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including TNF superfamily members, TNF ligands, and TNF-
responsive genes. The p53 mRNA levels did not change, but
there was a strong increase in MdM-2 mRNA, which is
induced in response to p53 to foster clearance (19). The
proapoptotic genes APAF1, BAX, PMAIP1, and MCL1 were
moderately upregulated. Two cell death-inducing DDFA-like
effectors were strongly downregulated (CIDEA, CIDEC), and
others moderately but consistently downregulated are:
CARD6, CARD10, FAS, BCL2L13, BNIP3, cytochrome c,
and AATK. There were strong increases in the genes involved
in DNA repair, PCNA and GADD45B, and also the cell cycle
arrest-associated mRNAs, CDKNA1 (pRB). Retinoblastoma
nuclear protein genes individually changed consistently over
time, but the transcript levels for some family members in-
creased while the levels decreased for others. The antiapoptotic
genes BCL2, BCL2-W, BAG1, and BAG4 declined in abun-
dance. However, the antiapoptotic genes, such as BCL2L11
(BCL2-XL), BCL2A1, BAG2, and the IAP-related survival
genes, including NAIP, c-IAP1, BIRC4, and survivin were
strongly upregulated (Table 2, Supplemental Table 6). There
were increases in the proinflammatory initiator caspases 1 and
4, but relatively little induction of the other caspases. The
mixture of transcript changes may reflect the different cell
types and fates in the WAT. Overall the changes at the
transcriptional level seem to favor cell cycle arrest and survival
rather than apoptosis.
Energy expenditure. One mechanism for lipid depletion that
has been proposed is an increase in energy expenditure via an
increase in thermogenic energy via UCPs. UCP1 and UCP2
transcript levels increased 26- and 4-fold, at abundance levels
that places them in the 95th and 90th percentiles in probe set
signal strengths, respectively, These values agree with the 33-
and 8-fold changes observed for UCP-1 and -2, respectively, in
the quantitative RT-PCR (QRT-PCR) analysis (Tables 5 and
6). These increases occurred 3–7 days after t10c12 CLA
treatment initiation, which is about when the most rapid fat loss
occurs (Fig. 1). Additionally, carnitine palmitoyltransferase 1
(CPT1) mRNA levels were increased (Table 4). The combina-
tion of increased transcript levels for UCP1 and CPT1 suggests
increased fatty acid oxidation is occurring.
Adipocyte transcription factors. Key transcription factors
regulating adipocyte differentiation and gene expression had
reduced expression levels as early as 24 h after t10c12 CLA
treatment. These include PPAR-, CAAT/enhancer binding
protein (C/EBP)-, retinoic acid receptor-x, and SREBP1 (Ta-
ble 7). There was also a transient downregulation on day 1 of
other transcriptional factors such as PPAR- coactivator 1
and  (Table 7). The changes in the transcripts for PPAR- and
C/EBP- were confirmed by QRT-PCR (Tables 5 and 6) as
were changes for preadipocyte factor-1 (Pref-1) and fatty acid
binding protein. The reduced expression of the transcription
factors that regulate the development and maintenance of
Table 5. Quantitative RT-PCR verification of selected mRNA signal changes
Days of trans-10 cis-12 Linoleic Acid Feeding
1 2 3 4 7
Gene Description Gene Symbol Average Relative Expression Value  SE (n  3)
Lipin 1- LPIN1- 1.50  0.2 0.55  0.1 0.51  0.1 0.85  0.1 0.78  0.1
Lipin 1- LPIN1- 0.36  0.0 0.43  0.1 0.53  0.1 0.21  0.0 0.21  0.0
CCAAT/enhancer binding protein- CEBPA 0.38  0.1 0.48  0.1 0.37  0.0 0.16  0.1 0.59  0.1
Peroxisome proliferative activated receptor- PPARG 0.14  0.0 0.57  0. 0.28  0.0 0.18  0.0 0.38  0.0
Fatty acid binding protein 4, AP-2 FABP-4 0.44  0.0 0.10  0.0 0.47  0.1 0.47  0.1 0.57  0.1
Preadipocyte factor-1 PREF-1 DLK-1 1.50  0.2 0.44  0.1 0.48  0.1 0.43  0.1 0.57  0.1
The average relative expression values shown are the expression values relative to the control mRNA of 2 microglobulin.
Table 6. Changes in relative and absolute signal values for uncoupling proteins in RP tissues
Gene Symbol Gene Description
Days of trans-10 cis-12 CLA Feeding
1 2 3 4 7 10 17
Microarray Fold Change in mRNA Levels
UCP1 uncoupling protein 1 20 26 14
UCP2 uncoupling protein 2 3.0 3.7 4.3 3.4 3.9
UCP3 uncoupling protein 3 0.3 0.2 0.2 0.3 0.2 0.2 0.2
Probe Set ID Microarray Probe Set Signal Values
UCP1 1418192_at 44 313 157 450 10,056 9723 4114
UCP2 1448188_at 1000 2684 3808 6250 5956 5250 4926
UCP2 1459740_s_at 1138 1943 3236 4235 3784 4054 4929
UCP3 1420657_at 242 327 230 193 285 296 157
Average Quantitative RT-PCR Relative Expression Values  SE (n  3)
UCP1 uncoupling protein 1 0.170.2 0.90.3 0.60.3 1.30.5 221.6 333 111.6
UCP2 uncoupling protein 2 1.30.4 2.80.6 5.01.2 4.01.2 7.91.3 6.01.2 3.71.2
For comparative gene expression, the microarray probe set signal values for the UCP1 and UCP2 at day 7 are higher than 98 or 95 percent of the genes on
the microarray, respectively.
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adipocyte physiology is consistent with the sustained reduction
of the mRNA transcripts for enzymes in metabolic pathways
associated with lipid and fatty acid anabolic pathways (Tables
3 and 4). For example, the PPAR--modulated genes that are
downregulated include key metabolic genes such as aP2, SCD,
LPL ACC, FASN, and Glut4 (Table 4).
Downregulation of lipin 1 in adipose tissue. Lipin 1 tran-
scripts were consistently downregulated two- to sevenfold by
t10c12 CLA treatment at the different time points (Table 7).
The lipin 1 gene (Lpin1) may play a role in t10c12 CLA-
mediated lipid loss because a genetic mutation of the gene
causes a lypodystrophy (38) with symptoms remarkably simi-
lar to the syndrome caused by t10c12 CLA feeding. Two
alternatively spliced Lpin1 variants have been characterized,
lipin- and lipin-. The microarray probe sets either were
specific for the larger lipin- transcript or detected the mRNA
portions in common between the two forms. RT-PCR primer
sets that distinguish these two forms (37) were used both to
confirm the microarray expression results and to better distin-
guish the two types of mRNAs by QRT-PCR of mRNA from
control and t10c12 CLA-treated RP tissues (Table 5). There
was a transient increase in the relative mRNA abundance for
lipin- on day 1 and modest reductions in expression thereaf-
ter. The significant differential downregulation of lipin- was
confirmed (Table 5). The relative abundances of the two
alternatively spliced Lpin1 mRNAs were determined by per-
forming endpoint RT-PCR using two primers that produce
different size products for the lipin- and lipin- mRNA
forms. The lipin- mRNA form was found to be the major
form of Lpin1 mRNA in the adipose tissues (Supplemental Fig.
3). This is in contrast to the higher relative ratio of the lipin-
form in 3T3L1 mRNAs (Ref. 37 and Supplemental Fig. 3). The
significant reduction of the much more abundant lipin-
mRNA is consistent with the microarray results, as the more
modest changes in the lipin- mRNA would not contribute to
detectable differences on the microarray probe set that detects
the combined amounts of both of the Lpin1 mRNAs splice
isoforms.
Table 7. A subset of changes in nuclear genes and transcription regulators detected by Affymetrix array analysis
Gene
Symbol Gene Description Days of CLA Feeding
Associated With Adipocyte Differentiation and Functions 1 2 3 4 7 10 17
CEBPA CCAAT/enhancer binding protein (C/EBP) 0.3 0.5 0.4 0.4 0.5 0.5 0.5
EIF4EBP1 eukaryotic translation initiation factor 4E binding 0.5 0.4 0.5 0.4 0.4 0.4 0.4
EIF4EBP2 eukaryotic translation initiation factor 4E binding n.c. n.c. 0.7 0.6 0.5 0.5 0.5
LPIN1 lipin 1 0.2 0.4 0.2 0.3 0.3 0.3 0.2
PPARGC1 peroxisome proliferative activated receptor, 0.5 0.6 0.4 0.5 n.c. n.c. n.c.
PPARG peroxisome proliferative activated receptor, 0.3 0.6 0.4 0.4 0.5 0.5 0.6
PPARGC1 peroxisome proliferative activated receptor, 0.2 n.c. n.c. n.c. n.c. n.c. n.c.
NR1H3 nuclear receptor subfamily 1, group H, member 3 0.4 n.c. n.c. n.c. n.c. n.c. n.c.
SREBF1 sterol regulatory element binding transcription 0.2 0.4 0.3 0.3 0.4 0.3 0.3
SREBF2 sterol regulatory element binding transcription 2.8 2.8 3.0 2.1 n.c. n.c. n.c.
RXRG retinoid X receptor, gamma 0.3 0.7 0.4 0.4 0.4 0.4 0.5
WBSCR14 Williams Beuren syndrome chromosome region 0.3 0.3 0.2 0.1 0.1 0.2 0.2
NRIP1 nuclear receptor interacting protein 1 0.5 0.3 0.3 0.4 0.4 0.3 0.4
NR3C1 nuclear receptor subfamily 3, group C, member 1 0.4 0.4 0.3 0.6 0.6 0.5 0.6
PPARGC1 peroxisome proliferative activated receptor, 0.2 n.c. n.c. n.c. n.c. n.c. n.c.
NR1D1 nuclear receptor subfamily 1, group D, member 1 0.5 0.6 0.3 0.3 0.3 0.3 0.3
CEBPD CCAAT/enhancer binding protein (C/EBP), delta 4.3 n.c. n.c. n.c. n.c. n.c. n.c.
THRA thyroid hormone receptor, alpha 0.4 0.4 0.5 0.4 0.5 0.5 0.8
Transcription Factors Associated With Miscellaneous Functions
RORC RAR-related orphan receptor C 0.4 0.2 0.2 0.2 0.3 0.2 0.2
PLAGL1 pleiomorphic adenoma gene-like 1 0.3 0.4 0.4 0.3 0.4 0.5 0.8
ATF3 activating transcription factor 3 16.0 6.1 11.3 17.1 27.9 26.0 26.0
ATF4 activating transcription factor 4 7.0 4.3 5.3 4.3 3.0 3.0 4.3
MAFF v-maf musculoaponeurotic fibrosarcoma 12.1 3.5 2.6 3.5 2.3 4.0 2.6
EGR1 early growth response 1 8.0 1.6 2.1 2.8 2.6 5.3 2.6
EGR2 early growth response 2 6.5 8.0 8.0 10.6 16.0 21.1 21.1
EGR3 early growth response 3 3.5 2.0 n.c. 2.3 3.5 6.5 4.9
EAF1 ELL associated factor 1 7.5 2.0 2.3 2.0 1.7 1.9 1.9
FOS v-fos FBJ murine osteosarcoma viral oncogene 7.5 17.1 19.7 26.0 13.9 14.9 12.1
FOSL1 FOS-like antigen 1 21.1 3.5 7.5 10.6 2.6 4.3 2.6
FOSL2 FOS-like antigen 2 3.5 2.0 n.c. n.c. n.c. 1.6 1.5
DNMT3L DNA (cytosine-5-)-methyltransferase 3-like 7.5 1.9 2.3 2.3 2.0 2.3 1.7
MYC v-myc myelocytomatosis viral oncogene 7.5 n.c. 2.5 3.5 2.6 4.0 2.3
DDIT3 DNA-damage-inducible transcript 3 6.5 1.5 3.0 4.6 3.7 3.7 3.2
JUN v-jun sarcoma virus 17 oncogene homolog 4.6 2.0 2.6 2.3 2.3 2.3 2.5
JUNB jun B proto-oncogene 5.3 2.5 3.2 4.3 4.3 5.3 4.3
DSCR1 Down syndrome critical region gene 1 5.3 n.c. 1.6 1.7 1.7 1.9 1.6
RELB v-rel reticuloendotheliosis viral oncogene 4.0 n.c. n.c. n.c. 1.9 1.7 2.0
TGIF TGFB-induced factor (TALE family homeobox) 4.0 2.5 3.2 3.5 4.0 4.9 4.9
NFKBIZ nuclear factor of kappa light polypeptide gene 4.0 2.0 n.c. n.c. n.c. 2.6 3.7
The values represent fold-change relative to control where control  1.0. A full subset is available in the supplemental data set.
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Chemokines and inflammation. IL-6 increased within a 24-h
period, was slightly elevated at 48 h, and subsided at later time
points. Sustained increases in the levels of the mRNAs of
TNF--responsive receptors and responsive genes were found
over the longer term (Table 8). Increases in mRNAs of IL1B,
IL10, IL15, IL17, and in the receptors IL1RN, IRAKB, ILR1,
IL10R; IL10RA, IL10RB, IL17R, IL13R, IL13RA, and IL2RT
were also observed. The mRNA levels for the NFKB family of
related proteins NFKBIA, NFKBIB, NFKBIE, and NFKIBIZ
also increased.
Extracellular factors (CCL7 or MCP-7) CCL4 or MPlB are
increased as are other cytokines and cytokine receptors. At
least 28 CXCL or CCL motif genes were strongly induced (2-
to 30-fold) in the RP tissue as a result of t10c12 CLA feeding.
An examination of the signaling pathways impacted (Table 2)
shows 8 of the 20 pathways listed are directly involved in
inflammation, including IL-6, IL-2, IL-4, JAK/STAT, Beta cell
receptor, chemokine, ERK/MAPK, and phosphatidylinositol
3-kinase/AKT signaling. Finally, a high proportion of the
transcription factors with relatively strong signal increases is
known to be associated with responses to inflammation and
TNF- or NF-B modulation (Supplemental Tables 2 and 5),
strengthening the conclusion of a strong inflammatory
response.
Table 8. A subset of mRNA changes in genes of characterized and putative adipocytokines and associated
inflammation detected by Affymetrix array analysis
Days of CLA Feeding
Gene Symbol Gene Description 1 2 3 4 7 10 17
DF D component of complement (adipsin) 0.6 0.4 0.4 0.4 0.2 0.2 0.1
ADIPOQ adiponectin 0.5 0.4 0.5 0.5 0.5 0.5 0.6
ADIPOR2 adiponectin receptor 2 0.4 0.6 0.3 0.4 0.4 0.4 0.4
PBEF1 visfatin n.c. 0.5 0.4 0.5 n.c. n.c. n.c.
LEP leptin 0.2 n.c. 0.5 0.3 0.2 0.1 0.2
RETN resistin 0.6 0.3 0.3 0.4 0.3 0.3 0.3
RBP4 retinol binding protein 4, plasma 0.5 0.2 0.3 0.2 0.2 0.1 0.2
VEGF vascular endothelial growth factor 0.6 0.3 0.4 0.3 0.3 0.4 0.4
VEGFB vascular endothelial growth factor B 0.3 0.2 0.2 0.2 0.2 0.2 0.2
SERPINE1 serine proteinase inhibitor, PAI-1 55.7 12.1 14.9 5.3 5.7 9.2 7.5
TNF tumor necrosis factor 1.6 n.c. 1.6 1.5 n.c. n.c. n.c.
IL6 interleukin 6 (interferon, beta 2) 18.4 1.7 n.c. n.c. n.c. n.c. n.c.
IL1B interleukin 1, beta 6.5 1.7 1.9 n.c. n.c. 1.5 1.4
CASP1 caspase 1, apoptosis-related (interleukin 1, beta, convertase) 1.6 2.3 2.5 3.2 4.6 4.3 4.6
CASP4 caspase-4, Interleukin 1 beta convertase homolog, ICH2 8.0 2.5 2.8 3.2 3.0 3.5 4.0
IL1RN interleukin 1 receptor antagonist 4.0 18.4 27.9 73.5 32.0 17.1 7.5
PTX3 pentraxin-related gene, IL-tB induced 78.8 7.5 24.3 36.8 11.3 21.1 21.1
IKBKB inhibitor of kappa light polypeptide gene enhancer in B-cells,
kinase beta (IKK-beta)
1.5 1.5 2.0 1.4 n.c. n.c. n.c.
IKBKE inhibitor of kappa light polypeptide gene enhancer in B-cells,
kinase epsilon (IKK epsilon)
1.9 3.5 4.6 7.0 5.3 5.7 4.6
IL10 interleukin 10 n.c. 3.5 4.6 4.3 2.3 2.1 n.c.
NOS3 nitric oxide synthase 3 0.3 0.2 0.2 0.2 0.2 0.1 0.1
(endothelial cell)
NOSTRIN nitric oxide synthase trafficker n.c. 3.0 4.3 4.3 4.3 4.9 4.9
IL15 interleukin 15 n.c. n.c. 2.1 1.7 6.1 6.5 10.6
PTGS2 prostaglandin-endoperoxide synthase 2 (Cox-2) 2.1 n.c. n.c. n.c. 1.4 1.4 1.4
PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa n.c. 3.0 2.6 4.6 5.3 4.3 5.3
PTGER3 prostaglandin E receptor 3 (subtype EP3) 0.2 0.4 0.3 0.3 0.2 0.2 0.2
PTGER4 prostaglandin E receptor 4 (subtype EP4) 4.0 3.0 3.5 2.8 2.3 2.8 3.7
PTGES prostaglandin E synthase 0.4 0.3 0.2 0.3 0.2 0.2 0.2
PTGER3 prostaglandin E receptor 3 (subtype EP3) 0.2 0.4 0.3 0.3 0.2 0.2 0.2
PTGER4 prostaglandin E receptor 4 (subtype EP4) 4.0 3.0 3.5 2.8 2.3 2.8 3.7
SPP1 secreted phosphoprotein 1 4.6 119.4 84.4 147.0 9.8 21.1 22.6
ADFP adipose differentiation-related protein 1.4 1.7 1.5 2.3 1.6 1.4 n.c.
S100A9 S100 calcium binding protein A9 11.3 8.0 n.c. n.c. n.c. n.c. n.c.
ANGPT2 angiopoietin 2 n.c. 1.5 3.7 4.3 2.8 2.8 2.8
NGFB nerve growth factor, beta 4.9 3.7 1.9 3.5 n.c. n.c. n.c.
SAA3 serum amyloid A 3 4.3 8.0 4.3 3.7 3.7 3.5 3.2
LGALS3 lectin, galactoside-binding, soluble, 3 13.0 22.6 27.9 32.0 27.9 21.1 16.0
THBS1 thrombospondin 1 12.1 2.6 3.5 2.6 2.5 7.0 3.7
HSPA1B heat shock 70-kDa protein 1B 73.5 4.3 8.0 3.5 2.5 3.2 3.5
HSPA1A heat shock 70-kDa protein 1A 55.7 3.0 5.3 3.0 1.9 2.6 3.0
TIMP1 tissue inhibitor of metalloproteinase 1 9.8 42.2 8.6 12.1 5.7 11.3 8.0
GLIPR1 GLI pathogenesis-related 1 (glioma) 3.7 11.3 12.1 18.4 34.3 32.0 45.3
TIMP1 tissue inhibitor of metalloproteinase 1 9.8 42.2 8.6 12.1 5.7 11.3 8.0
CSF1 colony stimulating factor 1 6.1 2.6 1.6 n.c. n.c. 1.9 2.0
CXCL or CCL*
The values represent fold-change relative to control where control  1.0. *CXCL ot CCL motif genes  28 genes, 2- to 30-fold induction, see supplemental
data.
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DISCUSSION
A range of feed intake responses have been found in mice,
for a number of different genotypes, that were fed mixed or
pure isomers of CLA. These reports generally agree that
differences in feed intake, when observed, do not account for
CLA-induced WAT weight loss (17, 22, 36). For example,
AKR/J male mice fed a diet containing 1% of mixed isomers
of CLA, containing 41% of the t10c12 CLA isomer, showed no
reduction in feed intake or body weight relative to control mice
after 2 wk of feeding while maintaining a 40% reduction in RP
WAT mass (10). In a prior study from the same group, a
suppression of feed intake was observed that was later inter-
preted to be possibly due to feed aversion resulting from
simultaneous changes in diet and CLA treatment (10). Reduc-
tions in feed intake (11%) and total body weight were observed
with MC colony mice fed a diet containing a 0.5% CLA as a
mixture of c9t11 and t10c12 isomers with a concurrent loss of
49–70% of the mass of the RP WAT (18). However, a second
study under the same conditions with ML or MH colony mice
showed no reduction in feed intake or body weight while still
showing similar reductions in body fat (18). The range of WAT
weight losses reported in different studies may be due to
diet-genotype interactions, but this has not been conclusively
demonstrated. We found no reduction in feed intake or body
weight in our study, facilitating the assignment of the 75% or
more reduction in RP WAT weight to the metabolic effects of
consuming dietary t10c12 CLA.
A common and surprising finding in many CLA-feeding
experiments is that the total body weights of control and treated
animals are often similar despite the reduced fat content of the
CLA-fed mice. This can be explained in part by the increase in
liver and spleen size in some experiments (10, 18, 50) and the
reduced caloric content of the carcasses of the CLA-fed ani-
mals (48). In this latter study BALB/c male mice were fed
mixed CLA isomers containing 0.45% t10c12 CLA for 39
days. The body weights of the CLA-fed mice were 96% of the
controls, but the energy content of these mice was only 63% of
the control mice due to a decrease in fat content and increase
in water content (48).
A recent study of the transcriptome response of obese mice
fed 1% t10c12 CLA for 5 or 14 days found a 30% weight loss
in epididymal adipose tissues and evidence of expression
changes for genes involved with apoptosis, energy expenditure,
fatty acid oxidation, lipolysis, inflammation, lipogenesis, and
blockage of preadipocyte differentiation (21). The number of
gene expression changes was relatively small with only 29 and
125 genes altered twofold or more (P  0.01) after 5 and 14
days, respectively (21). Our experiments with RP adipose
tissues found between 2,682 and 4,216 genes changed expres-
sion levels by at least twofold (P  0.01, Table 1). The classes
of transcript changes generally agree with those found in the
earlier study (21) and considerably expand the description of
genes that respond to t10c12 CLA. This larger number of
detected changes resulted from the recent availability of the
Affymetrix GeneChip Mouse Genome 420 2.0 microarray that
surveys over 34,000 mRNA transcripts.
Apoptosis
Our histological data indicate the major mechanism of de-
lipidation is not mediated by apoptosis. We found at least 85%
of the number of adipocytes in the control WAT are still
present in the WAT under conditions where the treated tissue
has lost 75% or more of its mass. This is consistent with results
from our and other studies showing reduced adipocyte size is
the major effect of t10c12 CLA (1, 4, 9). Some studies have
found indications of apoptosis (18, 34, 50), although the
percentage of the cells lost from the tissues was not established
in those studies. We observed a 47% loss of total cells present
in the WAT when the tissue lost 75% or more of its mass. The
extent of cell loss may depend on the extent of WAT mass loss,
which also varied between studies (reviewed in Refs. 22 and
35). CLA has been reported to inhibit preadipocyte differenti-
ation in 3T3-L1 cells (3, 27), possibly causing the observed
adipocyte loss through the lack of replacement of older adipo-
cytes. The reduction in the transcript levels of many key
adipocyte differentiation factors such as PPAR- and C/EBP-
is likely to prevent preadipocytes from differentiating (12)
although we did not see an accumulation of the Pref-1 tran-
script that is diagnostic of preadipocytes (44). Transcripts of
genes involved in apoptotic pathways were found to be both
increased and decreased with no clear conclusion about the
activity of these pathways apparent from the changes in tran-
script levels alone. This may be due in part to the different cell
types in the WAT and in part to the posttranscriptional nature
of the major part of the apoptosis machinery.
Changes in Energy Import, Biosynthesis, and Storage
Two major sources of metabolites that are converted and
stored in the adipocytes’ lipid droplet are glucose, imported via
the insulin sensitive glucose transporter system, and fatty acids,
available from the hydrolysis of extracellular VLDL bound
triglycerides via lipoprotein lipase (32). Our results agree with
and extend previous reports showing a large decrease in tran-
scripts for genes responsible for glucose and fatty acid uptake
(21), including the insulin-sensitive glucose transporter gene
GLUT4 (9), the facilitated glucose/fructose transporter mem-
ber SLC2A5, and numerous genes for biosynthesis of fatty
acids (Table 4). Additionally, most of the transcripts involved
with anabolic processes such as gluconeogenesis, citrate acid
cycle, fatty acid metabolism, proprionate, buturonate, and ste-
rol biosynthesis were strongly downregulated (Tables 3 and 4),
indicating a greatly reduced capacity for the biosynthesis of
fatty acids and sterols. This is consistent with the increased
insulin resistance observed in many studies in CLA-fed mice
(reviewed in Ref. 22) and is in agreement with the experimen-
tal observations demonstrating uptake of glucose and fatty
acids is reduced in cultured human adipocytes (4).
Additional genes with reduced mRNA levels that are ex-
pected to reduce TG synthesis include a key subunit of acyla-
tion-stimulating protein (31), caveolin I (41), and Lipn1 (39).
Recent studies with the yeast lipn1 homolog PAH1 and mam-
malian LIPN1 protein indicate they have a phosphatidate
phosphatase activity that regulates the flow of phospholipids
into membranes or TAG production (15). When the PAH1
protein is absent or phosphorylated, an excess of phospholipids
and reduced amounts of TAG are produced. This new bio-
chemical role of LIPN1 may indirectly account for gene
expression changes previously considered to be a direct regu-
latory affect on transcription (15, 42). The reduction in the
mRNA levels for the carbohydrate responsive element binding
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protein (ChREBP) is also a likely factor because ChREBP-
deficient mice show symptoms of reduced adiposity and down-
regulation of lipid biosynthetic enzymes (23).
Increased Energy Expenditure
Evidence suggesting an increased cellular energy expendi-
ture in RP tissues is the 26- and 4-fold increase in mRNA
levels for UCP1 and UCP2, respectively. Similar results of
increased UCP1 or UCP2 transcript or activity levels have been
observed in some (18) but not other studies of CLA-fed mice
(21, 53, 54). UCP1 plays a role in mitochondrial energy
expenditure, whereas UCP2’s role is still emerging and appears
not to be involved in thermogenesis (29, 43). Further support-
ing a possible increase in cellular energy expenditure was the
increase in CPT1 mRNA. CPT1 is considered a rate-limiting
step in fatty acid beta-oxidation in the mitochondria (2) and has
been previously observed to increase in CLA-fed mice (36) and
rats (30). CLA-fed mice have been reported to have an in-
creased energy expenditure, and 74% of the energy loss was
found to be due to increased metabolic heat output (49). The
large UCP1 and CPT1 transcript increases observed in this
study and by others (21, 22) suggest that caloric energy
expenditure via mitochondrial heat loss in the WAT of the
t10c12 CLA-fed mice is occurring. The reduced mRNA levels
of regulatory factor Rip140 observed may be part of the
mechanism responsible as mice knockouts of this gene show
increased UCP1 and CPT1 levels (7, 40).
Energy Export
Lipolysis of the TGs in the lipid droplet and export of free
fatty acids and glycerol make up the major means of energy
export from living adipocytes. An increased rate of lipolysis
has been reported for cultured adipocytes (5), but no increase
in rate was found in CLA-fed mice (55). The two- to sevenfold
declines in the levels of the transcripts of the key lipolytic
enzymes involved in fatty acid transport out of in t10c12
CLA-treated adipocytes indicate a reduced rate of hydrolysis is
likely occurring, but some residual hydrolytic activity is likely
as these transcripts are still in the 90th percentile of the most
abundant mRNA signals.
Signaling and Inflammation
The current limited understanding of the initial molecular
responses to t10c12 CLA include a desaturation step by a
delta-six desaturase that is required to produce an active t10c12
CLA metabolite (16), activation of a PTX-sensitive GPCR,
activation of the U1026-sensitive MEK/ERK pathway, activa-
tion of kamebakaurin-sensitive NF-B pathway, and induction
of IL-6 (4). IL-6 was necessary for the CLA response in
cultured human adipocytes (4) and was highly induced 24 h
after t10c12 CLA treatment in the present analysis. Its levels
declined to normal values after 48 h. The role TNF- plays is
unclear (8), and TNF- mRNA levels increased by 20% or less
in our experiments. A transient increase in TNF- was ob-
served at 3 h after CLA treatment in cultured human adipose
cells (8) and might have subsided before our earliest time point
at 24 h. Evidence for IL-1 as a means to activate NF-B was
the sustained upregulation of IL-1- and IL-1-induced genes
CASP1, CASP IV, and PTX3 (Table 8). Either TNF- or
IL-1 signals are capable of activating NF-B via the NF-B
kinase. Activated NF-B and ERK1/2 may constitute key steps
to induce the inflammatory response (8), including IL-6 induc-
tion and reduction of PPAR- activity, one of the key adipo-
cyte regulatory proteins (33). The mRNA levels increased for
some members of the NF-B family including IBKB,
IBKG, and the inhibitors of NF-B activation, NFBIA and
NFBIB, possibly due to feedback mechanisms to regulate the
inflammatory responses. Our microarray analyses are consis-
tent with activation of these pathways, particularly with the
large changes in cytokine transcript levels described below.
The numerous cytokines transcripts that change in abun-
dance in response to t10c12 CLA feeding can be organized into
two classes (Table 8): 1) those secreted factors associated with
endocrine and paracrine functions that declined, including
leptin, resistin, adiponectin, adipsin, and visfatin; and 2) the
50 mRNAs associated with inflammation that increased,
including IL-1, 6, 10, 15, and 17, and the receptors IL1RN,
IRAKB, ILR1, IL10R, IL10RA, IL10RB, IL17R, IL13R,
IL13RA, and IL2RT. Additionally, the transcripts increased for
30 of the CXC and CC ligand family of cytokines and
extracellular factors (CCL7 or MCP-7), CCL4 or MPlB (Table
8 and Supplemental Table 4).
Summary
One limitation of WAT mRNA transcript array data is that
it averages the transcript abundance across the several major
cell types in WAT including adipocytes, stromal-vascular and
connective fibroblasts, vascular endothelial cells, and immune
cells. Nonetheless several trends are apparent. The t10c12
CLA-mediated mRNA changes suggest that the dynamic equi-
librium of fatty acid turnover in WAT (25) could be shifted
toward net export because very little import or biosynthesis
appears to be occurring while presumably maintaining a re-
duced export capability. Sustained conditions of very little
import and recurring export could result in considerable deple-
tion of the lipid droplet. Together with an increase in cellular
energy expenditure, reduced preadipocyte differentiation due
to reduction of key regulatory proteins, and cell loss due to
apoptosis, these combined changes seemingly account for the
severe lipid and tissue loss observed in RP tissues. The sur-
prisingly large contingent of induced cytokine-related genes
may accelerate this process.
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